Colony Group’s Indaptus Therapeutics INDP Stock Holding History

Colony Group’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5	Closed	-$3K	–	746
2020 Q3	$3K	Hold	5	–	–	﹤0.01%	719
2020 Q2	$3K	Buy	+5	New	+$3.09K	﹤0.01%	674

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HAG

HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Colony Group's INDP Position: Q4 2020 in Review

Colony Group sold out of Indaptus Therapeutics (INDP) in Q4 2020, closing a stake of 5 shares — an estimated $3K sold.

Colony Group first reported a position in INDP in Q2 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 18 funds tracked by Wall St. Rank hold INDP as of Q4 2020.

Colony Group reported no remaining Indaptus Therapeutics position as of Q4 2020 after selling out during the quarter.
Colony Group sold 5 Indaptus Therapeutics shares in Q4 2020, an estimated $3K.
Colony Group first reported a position in Indaptus Therapeutics in Q2 2020 and held it in 2 quarters.
Colony Group's Indaptus Therapeutics position peaked at $3K in Q3 2020.
18 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2020.

Based on Colony Group's 13F filing for Q4 2020, filed 16 Feb 2021.